Allergy Sales That Rose Up Your Nose

The Allergy Market in 2014
The Allergy Market in 2014

In 2014, two intranasal steroids for the treatment of allergic rhinitis received FDA approval for Rx-to-OTC switch—Sanofi’s Nasacort Allergy 24 Hour and GlaxoSmithKline’s Flonase Allergy Relief. Nasacort entered the OTC market in February 2014 and according to recently released data from Kline’s Nonprescription Drugs USA study, from February through December 2014, the product generated about $100 million in sales at the manufacturers’ level. Kline pegs the overall allergy market up 10.0% to over $1.8 billion in sales at the manufacturers’ level.Read More »

Kline’s Rx-to-OTC Switch Forecasting Model Found to Be Highly Accurate

Kline’s Rx-to-OTC Switch Forecasting Model Found to Be Highly AccurateAnalyzing and forecasting Rx-to-OTC switch sales for over 50 years at Kline, we have recently reviewed how accurate our forecasts have been over time. Over the past 8-10 years, Kline’s syndicated studies on Rx-to-OTC switch have included comprehensive written analyses as well as an Excel-based forecasting model that provides both a percentage probability of switch as well as forecasted OTC brand sales post-switch. Among brands that have been analyzed in Kline’s series of reports on Rx-to-OTC switch are Motrin, Nuprin, Monistat, Aleve, Claritin, Allegra, Zyrtec, Zantac, Pepcid, Nicorette, Nicotrol,
Plan B, Prilosec OTC, Prevacid, Zegerid, Miralax, Alli, Oxytrol for Women, and many others.Read More »

How Does Your Company’s Rx-to-OTC Switch Pipeline Compare to Competitors?

rx to otc switches
Rx-to-Otc switches

Recently, there has been increased switch activity with the FDA exploring the use of new technology to aid consumers when making purchase decisions and using switch medications, as well as more applications being submitted by the pharmaceutical industry to the agency.Read More »

Sales Resurgence of U.S. OTCs in 2013 Helps the Market Overcome Flat Sales Performance of the Past

Nonprescription Drugs USA According to Kline’s Nonprescription Drugs USA  study, the U.S. OTC market grew over 3.0% during 2013 to reach $23.5 billion at the manufacturers’ level.  Driven by strong sales gains in analgesics, upper respiratory, nutritional, and topical products, the market appears to be showing signs of recovery. This is partly due to the long-awaited rejuvenation of several brands that have posted steep declines in the recent past as a result of supply disruptions and recalls. Brands such as Novartis’ Excedrin and Johnson & Johnson’s Tylenol and Motrin IB have experienced strong gains in 2013 thereby helping the analgesics category to post very strong gains this past year while Pfizer’s Advil, Bayer’s Aleve, and private-label analgesics also posted gains in 2013. Read More »

Broader Opportunities in Rx-to-OTC Switch

Rx-to-OTCThere have been signs recently indicating that the environment is becoming ripe for more Rx-to-OTC switches. Since we last reported on this topic in August 2013, we saw the approval of two additional first-in-class switches in categories that would have been thought of as challenging five years ago. One is the first incontinence medication available for sale without a prescription, Merck’s Oxytrol for Women, and the other is the first nasal allergy steroid, Sanofi’s Nasacort Allergy 24HR.Read More »

Prominent OTC companies on hand at CHPA’s Market Exchange

Over-the-counter (OTC) medicines and                                                                        nutritional supplements play an increasingly vital role in America’s healthcare system. Sales continue to grow in spite of the recent recession, as customers seek cost-effective treatment options. Some OTC categories have even benefited from the economic downturn.Read More »